China generates roughly a third of ASML's revenue. A new House bill wants to cut that off. The EUV monopoly is real, but the valuation assumes a growth path that requires the China relationship to survive.
ASML makes the only machines capable of printing circuits at 7nm and below. Every major chipmaker, from TSMC to Samsung to Intel, depends on its extreme ultraviolet lithography systems to stay competitive. That is not a moat. That is a chokehold on the entire semiconductor industry.
But the stock trades at 46 times trailing earnings and 35.8 times EV/EBITDA. Those multiples require continued volume growth at attractive margins. And roughly 30% of that volume currently flows to Chinese customers.
A new House bill filed in April 2026 would expand export restrictions to include ASML's deep ultraviolet systems, which China currently uses freely. If it passes, ASML does not lose its monopoly. It loses a third of its near-term revenue base while it waits for other customers to absorb the displaced volume. The monopoly premium survives. The growth trajectory does not.
ASML's position in the semiconductor supply chain is genuinely unusual. Most technology moats are durable but contestable: a competitor with enough capital and talent can eventually replicate a cloud platform, a search engine, or an operating system. EUV lithography is different.
The machines cost approximately 380 million euros each. They contain over 100,000 components sourced from a global network of suppliers that has taken three decades to assemble. The light source, produced by a laser striking a tin droplet 50,000 times per second at a specific pulse rate, creates plasma that emits extreme ultraviolet light at 13.5 nanometers. The entire optical system must maintain tolerances measured in fractions of a nanometer while the machine operates in a near-vacuum.
China has been trying to develop a domestic equivalent for years. Its efforts have not come close. The ASML monopoly on EUV is not a matter of intellectual property or regulatory protection. It is a matter of physics, precision manufacturing, and supply chain depth that cannot be replicated on a policy timeline.
ASML also produces deep ultraviolet (DUV) systems, which use older technology to manufacture chips at larger nodes. These machines are not unique: Nikon and Canon produce competing equipment. But DUV still accounts for the majority of ASML's unit volume, and it is DUV that China currently buys in large quantities.
TickerXray Report
Get the complete ASML report with all 12 quantitative models, AI-generated investment thesis, and real-time data.
Revenue grew from 18.6 billion euros in 2021 to 32.7 billion euros in 2025, a compound annual growth rate of approximately 15%. Operating margins moved from 36.3% in 2021, compressed to 30.7% in 2022 as the company scaled manufacturing, and recovered to 34.6% in 2025. Net income reached 9.6 billion euros in 2025, up from 5.9 billion in 2021.
Those are strong numbers. But the margin trajectory reveals something important: operating leverage at ASML is real but not aggressive. Gross margins have held in the 51-53% range across the full period, barely moving despite significant revenue growth. The operating margin improvement in 2025 reflects volume absorption rather than structural margin expansion.
The free cash flow picture is more volatile. FCF was 9.9 billion euros in 2021, collapsed to 3.2 billion in 2023 as the company invested heavily in capacity, then recovered to 10.6 billion in 2025. The 2023 trough matters because it coincided with peak capex investment at a moment when Chinese customers were loading up on DUV machines ahead of anticipated restrictions. That pulled demand forward, which partly explains why the 2024 and 2025 revenue growth looks modest relative to the previous cycle.
ASML beat earnings estimates in six consecutive quarters from Q1 2024 through Q3 2025. The beat percentages were meaningful: 10.3%, 7.5%, 8.4%, 1.6%, 3.7%. Then Q4 2025 arrived: actual EPS of 7.34 euros versus a consensus estimate of 8.60 euros. A miss of 14.7%.
That is not a rounding error or a one-quarter anomaly. It reflects a backlog conversion issue. ASML's order intake in late 2024 slowed as customers, particularly in the memory segment, worked through existing inventory before placing new orders. The company's own guidance had flagged this, but the market expected ASML's monopoly pricing power to offset the volume softness. It did not, at least not in Q4.
The earnings miss matters because it arrived precisely when export restriction noise was accelerating. The market has two competing narratives running simultaneously: the bull case (AI capex supercycle drives insatiable EUV demand), and the bear case (China restrictions plus memory customer pause creates a two-year air pocket in volume). The Q4 miss was the first piece of concrete evidence in favor of the bear case.
Chinese customers accounted for approximately 29% of ASML's 2025 revenue. That figure is itself a product of restriction: China loaded up on DUV equipment in 2022 and 2023 before restrictions tightened, and some of that revenue has since moderated. The current 29% share represents the equilibrium after the initial DUV rush, not a peak.
The April 2026 House bill targeting expanded export restrictions on DUV equipment to China represents a qualitative escalation. The legislation, as reported on April 3, would bar ASML from selling equipment that it currently ships to Chinese fabs without restriction. That equipment is not EUV. It is the mature-node DUV machinery that powers a significant portion of Chinese semiconductor manufacturing capacity.
If the bill passes and is signed into law, ASML faces a binary outcome. In the optimistic version, TSMC and Samsung accelerate capacity additions and absorb the displaced volume within two to three years. In the pessimistic version, ASML's revenue growth stalls as the company waits for non-Chinese demand to catch up, while its cost base remains fixed against a contracted backlog.
The stock currently prices the optimistic version. The market's assumption is that AI-driven demand from TSMC, Samsung, and Intel is large enough to absorb the China volume and then some. That assumption may prove correct. But it requires three things to happen simultaneously: AI capex spending holds at current levels, non-China customers build capacity on an accelerated timeline, and no political escalation further restricts what ASML can supply to China in the interim.
The EUV monopoly is the most discussed aspect of ASML's competitive position, but the more operationally important point is the installed base. ASML has shipped over 200 EUV machines to date. Each machine requires ongoing service, parts, and software upgrades. The service revenue stream is growing faster than equipment revenue and carries higher margins.
This creates a recurring revenue dynamic that does not exist in most capital equipment businesses. Once a chipmaker installs ASML EUV systems, switching costs are not just financial. The entire fab process is designed around the machine's specific optical characteristics, overlay accuracy, and throughput specs. Replacing installed ASML equipment with a hypothetical competitor would require requalifying every layer of the manufacturing process. No one would do it.
The DUV installed base has a similar but weaker dynamic. Nikon and Canon do compete in DUV. They have done so for decades. ASML's DUV market share is dominant but not absolute, and the competitive pressure on DUV pricing is real. This matters because if DUV export restrictions expand, ASML does not just lose volume. It loses volume in a product segment where it does not have EUV-level pricing power.
ASML generated 10.6 billion euros of free cash flow in 2025, up from 9.5 billion in 2024 and dramatically above the 3.2 billion trough in 2023. The company returned 5.7 billion euros to shareholders via buybacks in 2025, the most aggressive repurchase program in at least five years.
The timing of that acceleration is notable. ASML bought back significant stock in 2021 at prices that now look prescient, then stepped back from buybacks in 2022 and 2023 as the stock climbed and capex demands absorbed cash. The 2025 buyback surge came as the stock sold off from its 2024 peak, suggesting management views the current price as a reasonable entry point for repurchases.
The balance sheet is clean. Net cash stands at approximately 10.2 billion euros, with 12.9 billion in cash against 2.7 billion of total debt. ASML has the financial capacity to sustain buybacks and dividends through a two-year demand pause if restrictions materialize. The question is not solvency. It is whether the growth trajectory that justifies 46 times earnings survives a China revenue reset.
ASML trades at 46 times trailing earnings and 35.8 times EV/EBITDA. On price-to-sales, the stock is at 15.8 times. These are not screaming-overvalued numbers for a monopoly with 34% operating margins and 10 billion euros of annual free cash flow. But they are not forgiving numbers either.
At current multiples, the market is pricing in sustained double-digit earnings growth for at least the next seven to ten years. The bull case that supports that growth requires AI infrastructure spending to remain at or above current levels, TSMC and Samsung to continue their capacity expansion programs, and the China revenue base to either hold steady or be replaced quickly by other customers.
Analyst consensus remains constructive: 22 strong buy ratings, 8 buy ratings, and only 1 strong sell against a price target of 1,475 dollars. That target implies meaningful upside from current levels. But consensus targets are set against a forward earnings estimate that was built before the April 2026 export restriction legislative push. If 30% of revenue faces material risk, the forward multiple expands, and the target comes down.
Sentiment over the past 30 days has been broadly positive, with normalized sentiment scores between 0.65 and 0.99 on most days. The April 3 news day is the first meaningful exception, with one article on US export restriction targeting pulling sentiment toward negative territory. That divergence between high institutional ownership enthusiasm and the emerging legislative risk is worth tracking.
The most immediate risk is the House bill targeting expanded DUV export restrictions. As reported on April 3, 2026, the proposed legislation would specifically target ASML as the company most affected by expanded China export controls. Even if the bill does not pass in its current form, the political direction is clear. Every iteration of US export restriction policy since 2019 has been more restrictive than the prior version.
The second risk is the backlog conversion cycle. ASML's business is driven by orders placed 12 to 24 months ahead of delivery. If Chinese customers are now uncertain about whether new machines can be imported, they may pause orders. A pause in Chinese order intake would not show up in revenue immediately. It would show up in backlog, then in revenue guidance, then in earnings. The market would see it coming with a lag.
The third risk is earnings estimate reversion. The Q4 2025 miss of 14.7% was the largest in years. The forward EPS estimates embedded in analyst models were built assuming a smooth ramp in EUV deliveries and stable DUV volumes. If DUV volumes face China restriction headwinds, both revenue and margins compress simultaneously: revenue falls as unit volume drops, and margins compress because fixed manufacturing costs are spread over fewer machines. The EUV monopoly insulates the long-term thesis but does not protect the next two years of earnings.
ASML is the best capital equipment business in the world. The EUV monopoly is durable, the margins are strong, the balance sheet is clean, and the installed base creates a recurring revenue stream that does not exist in most industrial businesses. None of that is in dispute.
The dispute is about what the next two years look like. The Q4 2025 earnings miss, the pending House legislation on DUV export restrictions, and the 30% China revenue concentration are three data points that the current valuation at 46 times earnings is not adequately discounting.
The stock likely finds a fair equilibrium somewhere between the AI supercycle bull case and the China restriction bear case. At current prices, the bull case needs to be mostly right. That is not a comfortable position when a bipartisan legislative push exists specifically to reduce ASML's ability to serve the customer who generates roughly one-third of its revenue.
Full forensic analysis of ASML
+ 6 more models included
150,000+ stocks covered
Global coverage across 60+ exchanges. Every report includes all 12 quantitative models and AI analysis.
View plansEvery report runs 12 quantitative models and generates an AI investment thesis. From Piotroski scores to manipulation detection -- get the full picture in seconds.
12 forensic models
Piotroski, Altman, Beneish, DuPont & more
AI investment thesis
Synthesized outlook on every stock
Manipulation detection
Spot red flags before they hit the news
150,000+ tickers
Global coverage across 60+ exchanges
Expected return
Forward return projections for every stock
Real-time data
Live prices, insider trades, news sentiment
Free accounts get 1 report per month. Pro gets unlimited.
Three weeks after we flagged High-NA risk, the Q1 2026 backlog print arrived. The bookings number was stronger than feared but the customer concentration deteriorated meaningfully. The thesis updates rather than reverses; ASML remains the best risk-reward in semiconductor equipment but the multiple deserves a sharper haircut.
Shares fell 3% on a TSMC delay to high-NA EUV rollout. The real story is a process node workaround that bypasses the most profitable tool in the ASML catalogue.
ASML trades at 41.5x forward earnings; Applied Materials at 36.5x. The premium has logic but not as much as the gap implies. One of these companies is materially mispriced.